Skip to main content

Table 2 Pathogens and antibiotic treatment of patients with VAP caused by A. baumannii

From: Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia

Variables All cases Survivors Non-survivors P value
( N= 337) ( N= 174) ( N= 163)
Pathogens     
Single microbial 180 (53.4) 98 (56.3) 82 (50.3) 0.269
Polymicrobial 157 (46.6) 76 (43.7) 81 (49.7)
P. aeruginosa 76 (22.2) 32 (18.5) 44 (27.0) 0.063
MRSA 49 (14.5) 18 (10.3) 31 (19.0) 0.024
K. pneumoniae 19 (5.6) 9 (5.2) 10 (6.1) 0.702
 Othersa 29 (8.6) 19 (10.9) 10 (6.1) 0.118
Groups of A. baumannii     
 DS 33 (9.8) 26 (14.9) 7 (4.3) <0.001
 MDR 72 (21.4) 49 (28.2) 23 (14.1)
 XDR 220 (65.3) 95 (54.6) 125 (76.7)
 PDR 12 (3.6) 4 (2.3) 8 (4.9)
Antibiotic treatment     0.110
 Single antibiotic 120 (36.0) 69 (40.4) 51 (31.5)
 Combined antibiotics 213 (64.0) 102 (59.6) 111 (68.5)
Time to start antibiotic     0.125
 Early (within 24 h) 307 (91.1) 163 (93.7) 144 (88.3)  
 Late (>24 h) 30 (8.9) 11 (6.3) 19 (11.7)
Empirical antibiotic treatment     <0.001
 Appropriate 212 (62.9) 133 (76.4) 79 (48.5)
 Inappropriate 125 (37.1) 41 (23.6) 84 (51.5)
  1. DS drug-sensitive, MDR multidrug-resistant, XDR extensively drug-resistant, PDR pandrug-resistant A. baumannii, MRSA methicillin-resistant Staphylococcus aureus.
  2. aOthers including E. coli, S. maltophilia, H. influenzae, methicillin-sensitive Staphylococcus aureus, and Enterococcus spp.